Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

References

• AhrenBFoleyJEThe islet enhancer vildagliptin: mechanisms of improved glucose metabolismInt J Clin Pract Suppl200815981418269436
   PubMedGoogle Scholar
• KeatingGMVildagliptin: a review of its use in type 2 diabetes mellitusDrugs2010702089211220964454
   PubMed Web of Science ®Google Scholar
• FonsecaVBaronMShaoQDejagerSSustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitusHorm Metab Res20084042743018401832
   PubMed Web of Science ®Google Scholar
• MatthewsDRDejagerSAhrenBVildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyDiabetes Obes Metab20101278078920649630
   PubMed Web of Science ®Google Scholar
• AhrenBFoleyJEBosiEClinical evidence and mechanistic basis for vildagliptin’s action when added to metforminDiabetes Obes Metab20111319320321205107
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJEKothnyWAssessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studiesVasc Health Risk Manag20117495721415917
   PubMedGoogle Scholar
• SchweizerADejagerSFoleyJECouturierALigueros-SaylanMKothnyWAssessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes populationDiabetes Obes Metab20101248549420518804
   PubMed Web of Science ®Google Scholar
• Ligueros-SaylanMFoleyJESchweizerACouturierAKothnyWAn assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trialsDiabetes Obes Metab20101249550920518805
   PubMed Web of Science ®Google Scholar
• HalimiSRaccahDSchweizerADejagerSRole of vildagliptin in managing type 2 diabetes mellitus in the elderlyCurr Med Res Opin2010261647165620441397
   PubMed Web of Science ®Google Scholar
• PratleyRERosenstockJPi-SunyerFXManagement of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapyDiabetes Care2007303017302217878242
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejagerSVillhauerEBDunningBEFoleyJEMechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansDiabetes Obes Metab20111377578321507182
   PubMed Web of Science ®Google Scholar
• FoleyJEJordanJWeight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experienceVasc Health Risk Manag2010654154820730070
   PubMedGoogle Scholar
• DejagerSSchweizerAMinimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes managementDiabetes Ther20112516622127800
   PubMedGoogle Scholar
• CaiLCaiYLuZJZhangYLiuPThe efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trialsJ Clin Pharm Ther12222011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• HalimiSMetformin: 50 years old, fit as a fiddle, and indispensable for its pivotal role in type 2 diabetes managementDiabetes Metab20063255555617296508
   PubMed Web of Science ®Google Scholar
• BouchouchaMUzzanBCohenRMetformin and digestive disordersDiabetes Metab201137909621236717
   PubMed Web of Science ®Google Scholar
• NicholsGAConnerCBrownJBInitial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practiceCurr Med Res Opin2010262127213520658898
   PubMed Web of Science ®Google Scholar
• LiCHungYJQamruddinKAzizMFSteinHSchmidtBInternational noninterventional study of acarbose treatment in patients with type 2 diabetes mellitusDiabetes Res Clin Pract201192576421251726
   PubMed Web of Science ®Google Scholar
• AubertREHerreraVChenWHaffnerSMPendergrassMRosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetesDiabetes Obes Metab20101271672120590749
   PubMed Web of Science ®Google Scholar
• LewisJDFerraraAPengTRisk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort studyDiabetes Care20113491692221447663
   PubMed Web of Science ®Google Scholar
• PiccinniCMotolaDMarchesiniGPoluzziEAssessing the association of pioglitazone use and bladder cancer through drug adverse event reportingDiabetes Care2011341369137121515844
   PubMed Web of Science ®Google Scholar
• BarnettAHCradockSFisherMHallGHughesEMiddletonAKey considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetesInt J Clin Pract2010641121112920236369
   PubMed Web of Science ®Google Scholar
• CryerPEThe barrier of hypoglycemia in diabetesDiabetes2008573169317619033403
   PubMed Web of Science ®Google Scholar
• Bourdel-MarchassonISchweizerADejagerSIncretin therapies in the management of elderly patients with type 2 diabetes mellitusHosp Pract (Minneap)20113972121441754
   PubMedGoogle Scholar
• DejagerSRazacSFoleyJESchweizerAVildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose studyHorm Metab Res20073921822317373638
   PubMed Web of Science ®Google Scholar
• FoleyJESreenanSEfficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetesHorm Metab Res20094190590919705345
   PubMed Web of Science ®Google Scholar
• GokeBHershonKKerrDEfficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metforminHorm Metab Res20084089289518726829
   PubMed Web of Science ®Google Scholar
• PanCYangWBaronaJPComparison of vildagliptin and acarbose monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabet Med20082543544118341596
   PubMed Web of Science ®Google Scholar
• RosenstockJBaronMADejagerSMillsDSchweizerAComparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Care20073021722317259484
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEvidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab2008101114112418355325
   PubMed Web of Science ®Google Scholar
• ScherbaumWASchweizerAMariAEfficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemiaDiabetes Obes Metab20081067568218248490
   PubMed Web of Science ®Google Scholar
• SchweizerACouturierAFoleyJEDejagerSComparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetesDiabet Med20072495596117509069
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSBosiEComparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trialDiabetes Obes Metab20091180481219476473
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXSchweizerAMillsDDejagerSEfficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetesDiabetes Res Clin Pract20077613213817223217
   PubMed Web of Science ®Google Scholar
• FerranniniEFonsecaVZinmanBFifty-two-week efficacy and safety of vildagliptin versus glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapyDiabetes Obes Metab20091115716619125777
   PubMed Web of Science ®Google Scholar
• FoleyJEBunckMCMoller-GoedeDLBeta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trialDiabetologia2011541985199121547496
   PubMed Web of Science ®Google Scholar
• IwamotoYKashiwagiAYamadaNEfficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled studyDiabetes Obes Metab20101270070820590747
   PubMed Web of Science ®Google Scholar
• AhrenBLandin-OlssonMJanssonPASvenssonMHolmesDSchweizerAInhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetesJ Clin Endocrinol Metab2004892078208415126524
   PubMed Web of Science ®Google Scholar
• MatikainenNManttariSSchweizerAVildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetesDiabetologia2006492049205716816950
   PubMed Web of Science ®Google Scholar
• AhrenBSchweizerADejagerSVildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetesJ Clin Endocrinol Metab2009941236124319174497
   PubMed Web of Science ®Google Scholar
• GerminoFWNoninsulin treatment of type 2 diabetes mellitus in geriatric patients: a reviewClin Ther2011331868188222136979
   PubMed Web of Science ®Google Scholar
• PornetCBourdel-MarchassonILecomtePTrends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (the 2001 and 2007 ENTRED surveys)Diabetes Metab20113715216121435929
   PubMed Web of Science ®Google Scholar
• LukashevichVSchweizerAShaoQGroopPHKothnyWSafety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trialDiabetes Obes Metab20111394795421733061
   PubMed Web of Science ®Google Scholar
• MeyersJLCandrilliSDKovacsBType 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustmentPostgrad Med201112313314321566423
   PubMed Web of Science ®Google Scholar
• SchweizerADejagerSFoleyJEShaoQKothnyWClinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trialsDiabetes Obes Metab201113556421114604
   PubMed Web of Science ®Google Scholar
• GersteinHCSantaguidaPRainaPAnnual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studiesDiabetes Res Clin Pract20077830531217601626
   PubMed Web of Science ®Google Scholar
• UnwinNShawJZimmetPAlbertiKGImpaired glucose tolerance and impaired fasting glycaemia: the current status on definition and interventionDiabet Med20021970872312207806
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med20083591577158918784090
   PubMed Web of Science ®Google Scholar
• RosenstockJFoleyJERendellMEffects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose toleranceDiabetes Care200831303517947341
   PubMed Web of Science ®Google Scholar
• UtzschneiderKMTongJMontgomeryBThe dipeptidyl peptidase- 4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucoseDiabetes Care20083110811317909087
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFerranniniESimonsonDCFasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptakeMetabolism1989383873952657323
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHBogardusCFoleyJERegulation of plasma lactate concentration in resting human subjectsMetabolism1990398598642198437
   PubMed Web of Science ®Google Scholar
• MonnierLColetteCDunseathGJOwensDRThe loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetesDiabetes Care20073026326917259492
   PubMed Web of Science ®Google Scholar
• AzumaKRadikovaZMancinoJMeasurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetesJ Clin Endocrinol Metab20089345946418042650
   PubMed Web of Science ®Google Scholar